Rani Therapeutics Holdings, Inc. (RANI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Rani Therapeutics is a clinical-stage biotherapeutics company developing the RaniPill, a drug-agnostic oral delivery platform designed to administer biologics and drugs orally. The company operates in one segment and is headquartered in San Jose, California. As of the reporting date, the company has no approved commercial products and has not generated significant product revenue.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Contract Revenue | $0.2 million | $0 |
| Net Loss (Consolidated) | $(24.0) million | $(28.1) million |
| Net Loss Attributable to Rani Holdings | $(14.0) million | $(14.3) million |
| Net Loss Per Share (Basic & Diluted) | $(0.40) | $(0.55) |
| Cash, Cash Equivalents & Marketable Securities | $10.2 million | $27.6 million (Dec 31, 2024) |
| Net Cash Used in Operating Activities | $(13.9) million | $(18.4) million |
| Total Debt (Current + Long-term) | $17.2 million | $24.6 million (Dec 31, 2024) |
| Accumulated Deficit | $(116.9) million | $(102.9) million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue: Recognized $0.2 million in contract revenue from evaluation services with Chugai Pharmaceutical Co., Ltd., compared to zero in the prior year period.
- Operating Expenses: Total operating expenses decreased by 14.6% to $22.7 million. Research and Development (R&D) expenses declined 11.9% to $12.1 million, and General and Administrative (G&A) expenses declined 17.4% to $10.6 million, primarily due to lower compensation costs.
- Liquidity: Cash and marketable securities decreased significantly from $27.6 million at year-end 2024 to $10.2 million at June 30, 2025, driven by operating losses and debt repayments.
- Debt: The company repaid $7.5 million of long-term debt during the period. Total debt outstanding is approximately $17.2 million, with $15.0 million classified as current.
- Capital Structure: In May 2025, the company issued a new Series D warrant for 13.2 million shares in exchange for the exercise of Series B and C warrants, generating $3.9 million in net proceeds.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for one year following the issuance of these financial statements. Existing capital resources are insufficient to fund operations beyond late September 2025 or to initiate pivotal clinical trials.
- Nasdaq Listing Status: The company received notices from Nasdaq in May and June 2025 regarding non-compliance with the Minimum Bid Price Requirement ($1.00) and the Market Value of Listed Securities ($50 million). The company has 180-day compliance periods to rectify these deficiencies or face delisting.
- Financing Needs: The company must raise substantial additional funds to complete clinical development, expand manufacturing, and commercialize products. Failure to secure funding could lead to operational delays, workforce reductions, or bankruptcy.
- Subsequent Events: In July 2025, the company entered into a securities purchase agreement raising $3.0 million through the sale of Class A common stock and pre-funded warrants.
- Scientific Progress: Preclinical data for RT-114 (oral GLP-1/GLP-2 agonist) and RT-116 (oral semaglutide) demonstrated bioequivalence to subcutaneous administration, supporting the rationale for clinical trials.
Investor Verification Checklist
- Verify the timeline and terms of the July 2025 equity offering and its impact on cash runway.
- Confirm the status of Nasdaq compliance plans regarding bid price and market value requirements.
- Assess the feasibility of raising additional capital given the "substantial doubt" going concern warning.
- Review the specific milestones required to trigger the next tranche of debt repayment or potential default.
- Monitor the progress of the RT-114 and RT-116 clinical trial initiations planned for late 2025.